CBIO Stock Crescent Biopharma, Inc.
US · NasdaqCMLast in our picks 2026-10-24 — not in the current list; analysis below is from that screen
Clinical pipeline catalysts create substantial upside, balanced against biotechnology execution risk.
Future value: $31.50 (+145.71%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Recent upgrade and strong-buy consensus support catalyst-driven appreciation.
- ▾Below 50-day MA (-19.77%)
- ▸~146% upside to price target
Is CBIO a buy right now?
Trend: CBIO is trading below the 50-day average (-19.77%), RSI 67 — neutral momentum, with a 3-month return of -24.28%.
Valuation & quality: Crescent Biopharma, Inc. trades on forward P/E -4.9, price-to-book 2.68; fundamentals show net margin 0.0%.
Analyst consensus: 6 analysts have a mean 12-month price target of $31.50 (+146.9% vs the last close; range $27.00 – $36.00), consensus rating “strong buy”.
Our screen: BUY (score 2) — Clinical pipeline catalysts create substantial upside, balanced against biotechnology execution risk.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +51.90% | +21.80% | -7.70% | -12.80% | -19.60% | +14.70% | -12.10% | -12.10% |
Fundamentals
Analyst price target
Technical signals
About Crescent Biopharma, Inc.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Sector: Healthcare · Industry: Biotechnology · United States · 69 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.